AI Science Tracker

Machine-learning selection identifies a six-metabolite signature for one-year cardiovascular events after PCI in type 2 diabetes

The First Affiliated Hospital of Zhengzhou University; Zhongnan Hospital of Wuhan University · 4 Jul 2022 · medicine

Discovery

Machine-learning selection identifies a six-metabolite signature for one-year cardiovascular events after PCI in type 2 diabetes

VSURF feature selection prioritized six serum metabolites—ADPR, 1-methylnicotinamide, D-ribose 5-phosphate, nicotinamide, L-tryptophan and phosphatidylcholine PC(36:2)—for one-year major adverse cardiovascular events (MACEs) after PCI in patients with type 2 diabetes. Random-forest and XGBoost models were tested in a nested case-control study and an independent prospective cohort of 301 patients; in the external cohort, reported AUCs were 0.92 and 0.94 for MACEs, respectively. The study also linked NAD+ biosynthesis perturbation to altered bioenergetics, inflammation and proliferation in high-glucose-cultured human aortic smooth-muscle cells.

Technology: VSURF random-forest variable selection; random forest and XGBoost classifiers

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Random-forest and XGBoost models were tested in a nested case-control study and an independent prospective cohort of 301 patients; in the external cohort, reported AUCs were 0.92 and 0.94 for MACEs, respectively. For the prognostic panel, the external cohort was collected before the development cohort. Separate cell experiments support the reported pathway mechanism, not prospective clinical performance of the panel.
  • Still unknown: The discovery component was a matched nested case-control sample (108 cases and 108 controls) from a single center; external validation was in a separate Chinese cohort of 301 patients, so transportability to other populations is unknown. AUCs describe retrospective/prospective cohort validation, not demonstrated clinical utility or improved patient outcomes. HASMC experiments do not prove the metabolites cause clinical events, and the paper states further mechanistic work is needed.
  • AI role: VSURF selected a six-metabolite feature set from serum metabolomic profiles. Random-forest and XGBoost models used that panel to predict one-year post-PCI outcomes; targeted metabolite testing evaluated the panel in a separate prospective cohort.

Evidence sources: https://link.springer.com/article/10.1186/s12933-022-01561-1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 51 of works of the same type, year and subfield (OpenAlex work metrics, 8 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.